Regeneron Pharmaceuticals Inc. is ramping up efforts to develop a set of coronavirus treatments, which could be available for testing or use in some patients within a few months, the drugmaker said on Thursday.
The U.S. Department of Health and Human Services is partnering with Regeneron Pharmaceuticals Inc. to develop a treatment for the coronavirus, making the drugmaker the latest to join the race to develop a therapy.
The U.S. Food and Drug Administration approved drugmaker Merck & Co.’s Ebola vaccine Ervebo, the first FDA-authorized vaccine against the deadly virus.
Johnson & Johnson filed for an approval from European regulators for the company’s two-dose experimental vaccine to protect against Ebola.
A team of Abbott scientists identified a new subtype of the human immunodeficiency virus, called HIV-1 Group M, subtype L.
The world’s first Ebola vaccine was recommended for approval by European drug regulators in a move hailed by the World Health Organization (WHO) as a “triumph for public health.”
Health authorities in Democratic Republic of Congo will introduce a Johnson & Johnson Ebola vaccine in November 2019 in the country’s eastern provinces, to counter the current outbreak.
GlaxoSmithKline transferred the company’s work on developing three potential vaccines against the Ebola and Marburg viruses.
As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials took four experimental vaccines to the front lines and began to administer it to patients who may have been exposed to the deadly virus.
An Ebola outbreak in Congo has been confirmed as the Zaire strain of the virus, the World Health Organization (WHO) said.